[1] |
SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics, 2016[J]. CA A Cancer J Clin, 2016, 66(1): 7-30.
doi: 10.3322/caac.21332
|
[2] |
ZHANG J, WANG Y Y, WENG H, et al. Management of non-muscle-invasive bladder cancer: quality of clinical practice guidelines and variations in recommendations[J]. BMC Cancer, 2019, 19(1): 1054.
doi: 10.1186/s12885-019-6304-y
pmid: 31694589
|
[3] |
POWLES T, BELLMUNT J, COMPERAT E, et al. Bladder cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up[J]. Ann Oncol, 2022, 33(3): 244-258.
doi: 10.1016/j.annonc.2021.11.012
|
[4] |
BABJUK M, BURGER M, CAPOUN O, et al. European association of urology guidelines on non-muscle invasive bladder cancer (Ta, T1, and carcinoma in situ)[J]. Eur Urol, 2022, 81(1): 75-94.
doi: 10.1016/j.eururo.2021.08.010
|
[5] |
WANG T W, YUAN H, DIAO W L, et al. Comparison of gemcitabine and anthracycline antibiotics in prevention of superficial bladder cancer recurrence[J]. BMC Urol, 2019, 19(1): 90.
doi: 10.1186/s12894-019-0530-0
|
[6] |
ZHENG R S, ZHANG S W, ZENG H M, et al. Cancer incidence and mortality in China, 2016[J]. J Natl Cancer Cent, 2022, 2(1): 1-9.
|
[7] |
LU J L, XIA Q D, LU Y H, et al. Efficacy of intravesical therapies on the prevention of recurrence and progression of non-muscle invasive bladder cancer: a systematic review and network meta-analysis[J]. Cancer Med, 2020, 9(21): 7800-7809.
doi: 10.1002/cam4.v9.21
|
[8] |
SIKIC D, ECKSTEIN M, WEYERER V, et al. High expression of ERBB2 is an independent risk factor for reduced recurrence-free survival in patients with stage T1 non-muscle invasive bladder cancer[J]. Urol Oncol, 2022, 40(2): 63.e9-63.63.e18.
|
[9] |
SYLVESTER R J, VAN DER MEIJDEN A P, OOSTERLINCK W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2 596 patients from seven EORTC trials[J]. Eur Urol, 2006, 49(3): 466-465; discussion 475-477.
doi: 10.1016/j.eururo.2005.12.031
|
[10] |
杨庆良, 陈志峰, 王军, 等. 非肌层浸润性膀胱癌患者经尿道膀胱肿瘤电切术后复发的影响因素[J]. 实用癌症杂志, 2022, 37(2): 309-311.
|
|
YANG Q L, CHEN Z F, WANG J, et al. Factors affecting recurrence of non-myometrial invasive bladder cancer after transurethral resection of bladder tumor[J]. Pract J Cancer, 2022, 37(2): 309-311.
|
[11] |
董建庭. 非肌层浸润性膀胱癌患者经尿道膀胱肿瘤电切术治疗后复发的现状及其危险因素分析[J]. 中国药物与临床, 2022, 22(3): 223-226.
|
|
DONG J T. Recurrence of non-muscle invasive bladder cancer and risk factors in patients after transurethral resection of bladder tumor[J]. Chin Remedies & Clin, 2022, 22(3): 223-226.
|
[12] |
薛炜, 邱建新, 桑楠, 等. 影响非肌层浸润性膀胱癌患者经尿道膀胱肿瘤电切术后复发的相关因素分析[J]. 实用医院临床杂志, 2019, 16(5): 30-33.
|
|
XUE W, QIU J X, SANG N, et al. Analysis of related factors influencing recurrence of patients with non-muscle invasive bladder cancer after transurethral resection of bladder tumor[J]. Pract J Clin Med, 2019, 16(5): 30-33.
|
[13] |
白恒舟, 乔保平. 200例非肌层浸润性膀胱癌复发及进展的危险因素分析[J]. 河南外科学杂志, 2017, 23(6): 39-41.
|
|
BAI H Z, QIAO B P. Analysis of risk factors for recurrence and progression of non-muscular invasive bladder cancer in 200 cases[J]. Henan J Surg, 2017, 23(6): 39-41.
|
[14] |
ZHANG Y Q, BREKKEN R A. Direct and indirect regulation of the tumor immune microenvironment by VEGF[J]. J Leukoc Biol, 2022, 111(6): 1269-1286.
doi: 10.1002/JLB.5RU0222-082R
|
[15] |
苟泓燊, 郑红岗, 段中琪. 经尿道膀胱肿瘤电切术术后即刻表柔比星灌注化疗在非肌层浸润性膀胱癌患者中的应用效果[J]. 癌症进展, 2021, 19(22): 2343-2346.
|
|
GOU H S, ZHENG H G, DUAN Z Q. Effect of immediate epirubicin infusion chemotherapy after transurethral resection of bladder tumor in patients with non-muscular invasive bladder cancer[J]. Oncol Prog, 2021, 19(22): 2343-2346.
|
[16] |
CUMBERBATCH M G K, FOERSTER B, CATTO J W F, et al. Repeat transurethral resection in non-muscle invasive bladder cancer: a systematic review[J]. Eur Urol, 2018, 73(6): 925-933.
doi: 10.1016/j.eururo.2018.02.014
|
[17] |
GONTERO P, SYLVESTER R, PISANO F, et al. The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade/grade 3 bladder cancer treated with bacille Calmette-Guérin[J]. BJU Int, 2016, 118(1): 44-52.
doi: 10.1111/bju.13354
|
[18] |
FLAIG T W, SPIESS P E, AGARWAL N, et al. Bladder cancer, version 3. 2020, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2020, 18(3): 329-354.
doi: 10.6004/jnccn.2020.0011
|
[19] |
MANO R, BANIEL J, SHOSHANY O, et al. Neutrophil-to-lymphocyte ratio predicts progression and recurrence of non-muscle invasive bladder cancer[J]. Urol Oncol, 2015, 33(2): 67.e1-67.e7.
|
[20] |
HEDRICK C C, MALANCHI I. Neutrophils in cancer: Heterogeneous and multifaceted[J]. Nat Rev Immunol, 2022, 22(3): 173-187.
doi: 10.1038/s41577-021-00571-6
|
[21] |
BULUT G, OZDEMIR Z N. Prognostic significance of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in metastatic colorectal cancer[J]. J Gastrointest Canc, 2022, 53(1): 1-6.
doi: 10.1007/s12029-021-00616-y
|
[22] |
ZHENG X Q, FAN H, LIU Y, et al. Hypoxia boosts aerobic glycolysis in carcinoma: a complex process for tumour development[J]. Curr Mol Pharmacol, 2022, 15(3): 487-501.
doi: 10.2174/1874467214666210811145752
|
[23] |
ZHAO R N, SHAN J H, NIE L H, et al. The predictive value of the ratio of the product of neutrophils and hemoglobin to lymphocytes in non-muscular invasive bladder cancer patients with postoperative recurrence[J]. J Clin Lab Anal, 2021, 35(8): e23883.
|
[24] |
CHENG X F, ZHOU X C, YI M, et al. Preoperative aspartate transaminase/alanine transaminase ratio as a prognostic biomarker in primary non-muscle invasive bladder cancer: a propensity score-matched study[J]. BMC Urol, 2021, 21(1): 136.
doi: 10.1186/s12894-021-00901-9
|
[25] |
HUANG J G, ZHAO L W, WANG K, et al. Controlling nutritional status score evaluates prognosis in patients with non-muscle invasive bladder cancer[J]. Cancer Control, 2021, 28: 10732748211021078.
|
[26] |
WANG Z Y, GAO W S, LI J, et al. Development and validation of a novel recurrence risk stratification for initial non-muscle invasive bladder cancer in the Han Chinese population[J]. J Cancer, 2020, 11(7): 1668-1678.
doi: 10.7150/jca.38649
pmid: 32194779
|
[27] |
GALESLOOT T E, GROTENHUIS A J, KOLEV D, et al. Genome-wide meta-analysis identifies novel genes associated with recurrence and progression in non-muscle invasive bladder cancer[J]. Eur Urol Oncol, 2022, 5(1): 70-83.
|
|
DALLA E, PICCO R, NOVARA G, et al. Identification of a gene signature for the prediction of recurrence and progression in non-muscle invasive bladder cancer[J]. Mol Biomed, 2022, 3(1): 9.
doi: 10.1186/s43556-022-00069-0
|